New Bone Drug Can Cut Fracture Risk In Elderly

Two studies suggest treatment works better than current medications

A first-of-its-kind osteoporosis drug lowers the risk of bone fractures as well as or better than current medicines, studies in older women and men with prostate cancer suggest.

Advisers to the Food and Drug Administration will review those studies and other data on the safety and effectiveness of Amgen Inc.'s denosumab Thursday, then recommend whether the agency should approve the genetically engineered drug.

Wall Street sees it as a potential blockbuster crucial to Amgen's future. But given the crowded market of treatments for the bone-thinning disease, doctors see its expected high cost as a big drawback.

GO HERE to read more.